Veliparib

DESCRIPTION
DESCRIPTION TARCEVA (erlotinib) is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor. Erlotinib is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7- ... Fetch This Document

Public Summary Of Opinion On Orphan Designation
7 March 2013 . EMA/COMP/668370/2010 Rev.1 . Committee for Orphan Medicinal Products . Public summary of opinion on orphan designation . Veliparib for the treatment of ovarian cancer ... Access Document

Gynecologic Cancer InterGroup (GCIG) General Assembly ...
Gynecologic Cancer InterGroup (GCIG) General Assembly - Ovarian Cancer Committee. Chair: P.Harter Co-Chair: A.Gonzalez. Closed/Ongoing trials 1st line Veliparib TBD PO. I . x 6 . Paclitaxel 80 mg/m. 2 (1 h) D1,8,15 Carboplatin AUC 6 (IV)* Placebo TBD PO ... Get Content Here

Current Trials Open To Accrual Breast Cancer
Current Trials Open to Accrual Breast Cancer As of 3/2/2015 REGISTRY/SYMPTOM MANAGEMENT AMG 20101102: Veliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (UIC IRB# 2014-0718) TRIPLE NEGATIVE ... Get Doc

B. Chyla 6, N. M. Mostafa6, M. Zhu , J. Qian , M. McKee , Y ...
6 Two doses of veliparib were assessed. Patients received veliparib 20 or 40 mg or placebo orally, twice daily on days 1 to 7 of each 28-day cycle. ... Fetch Full Source

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY PROTOCOL UPDATE TO ...
Alliance for clinical trials in oncology . alliance a071102 . a phase ii/iii randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with ... View Document

Linifanib (ABT-869), Enhances Cytotoxicity With Poly (ADP ...
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells Heng-Wei Hsua,c,d, Rosalia de Necochea-Campiond,e, Vonetta Williamsc, ... Document Retrieval

Merrimack To Present On Multiple Oncology Programs At The 2016 American Association For Cancer Research Annual Meeting
CAMBRIDGE, Mass., March 16, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data on its extensive oncology pipeline at ... Read News

For Protocol Combination With Temozolomide In Recurrent ...
Investigational agent veliparib in combination with carboplatin. The patient had disease progression in the CNS and was taken off the study. The event of seizure was assessed as not related to veliparib. ... Access Doc

PARP Inhibitors In Breast Cancer Treatment And Clinical Trials
A PARP inhibitor is a drug that blocks PARP proteins from performing their roles in repairing damaged cancer cells. Chemotherapy and radiation work by breaking the DNA of cells so that they may not reproduce. ... Read Article

A Phase II Evaluation Of The Potent, Highly Selective PARP ...
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a ... Access Document

Alliance A071102: A Phase II/III Randomized Trial Of ...
A071102 Version #1 Dev[3/23/15] Alliance A071102: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter ... Get Content Here

PHARMACOKINETICS OF THE COMBINATION OF VELIPARIB AND ...
Iv ABSTRACT: As part of a phase I clinical study, we assessed the pharmacokinetic properties of the combination of veliparib and temozolomide in patients with acute leukemias. ... Return Document

APhaseIStudyofVeliparibinCombinationwithMetronomic ...
APhaseIStudyofVeliparibinCombinationwithMetronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas (veliparib 60 mg daily with cyclophosphamide 50 mg daily), which was established as the MTD. Efficacy ... Access Doc

CURRICULUM VITAE Name: Richard Tuli, M.D., Ph.D.
CURRICULUM VITAE Name: Richard Tuli, M.D., Ph.D. Business Data: Address: CSMC Department of Radiation Oncology, 8700 Beverly Blvd., AC 1022 A Phase I study of veliparib (ABT-888) in combination with gemcitabine and intensity modulated ... Document Viewer

How To Say Or Pronounce Vein - YouTube
Get those medical secrets: http://www.health101.pw/Medical-Secrets.shtml This video shows you how to say or pronounce Vein. Audio is from cancer.gov. How to Say or Pronounce Veliparib - Duration: 0:07. Barrett Oneal 218 views. 0:07 ... View Video

Pronounce Medical Words ― PARP Inhibitor Medical 101. Subscribe Subscribed Unsubscribe 587 587. Loading Loading Working Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib - Duration: 1:05. OncLiveTV 196 views. 1:05 Top 27 Mispronounced Words - Duration: ... View Video

Clinical Trials With PARP Inhibitors In Defined Diseases
Agent(s) Histology and Reference* Cyclophosphamide ± Veliparib. Breast Cancer (ER+ *Publication or ClinicalTrials.gov identifier. Abbreviations: 5-FU, Fluorouracil; ER, estrogen receptor; FOLFIRI, Leucovorin, Fluorouracil, ... Access Content

Treatment - O'Reilly - Pancreatic Cancer Action Network
01585805 Gem + cisplatin ±veliparib ~70 PARPi (BRCA+) NCI, Lustgarten 01209111 Gem + erlotinib ±metformin 120 Multiple U. Amsterdam 01167738 PEXG ±metformin 82 Stem cells San Raffaele Microsoft PowerPoint - Treatment - O'Reilly Author: kbauer ... Access Full Source

Targeting DNA Repair With Combination veliparib (ABT-888) And ...
PHASE I STUDIES Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer ... Fetch Document

Talk:Veliparib - Wikipedia, The Free Encyclopedia
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. ... Read Article

Discordant In Vitro And In Vivo Chemopotentiating Effects Of ...
Cancer Therapy: Preclinical Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive ... Fetch Content

Material Safety Data Sheet - Cellagen Technology
Trade name: ABT‐888 (Veliparib) Catalog Number: C2888 Manufacturer/Supplier: Cellagen Technology LLC 5940 Pacific Mesa Court, Suite 206, CA 92121, USA TEL: (858) 633‐8197 FAX: (858) 228‐9964 2. COMPOSITION/DATA ON COMPONENTS: Chemical Name ... Fetch Here

Veliparib In Combination With Whole Brain Radiation Therapy ...
CLINICAL STUDY Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study Minesh P. Mehta • Ding Wang • Fen Wang • Lawrence Kleinberg• ... Document Retrieval

PARP Inhibitors In Lung Cancer
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center . Veliparib (ABT 888) Abbott Phase II Olaparib Astra Zeneca Phase II Iniparib*** Sanofi Aventis/BiPar Phase III ... Fetch Doc